A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience

Affiliations


Abstract

Background: Alemtuzumab, a humanized anti-CD52 monoclonal antibody, has been approved as a treatment in persons with active relapsing-remitting multiple sclerosis (RRMS). Real-world data in middle east is very limited. We aimed to evaluate the effectiveness and safety of alemtuzumab in a real-world clinical setting.

Methods: This observational, registry based study assessed persons with multiple sclerosis (PwMS) who were treated with alemtuzumab and completed at least follow up one year after second course. Baseline clinical and radiological characteristics within one year prior to alemtuzumab initiation were collected. The relapse rate, disability measures, radiological activity and adverse events at last follow-up visits were assessed.

Results: Data of seventy-three persons with multiple sclerosis (MS) was analyzed, of which 53 (72.6%) were females. Mean age and mean disease duration were 34.25 ± 7.62 and 9.23 ± 6.20 years respectively. Alemtuzumab was started in 32 (43.8%) naïve patients due to highly active disease and in 25 (34.2%) (PwMS) who were on prior therapies and in 16 (22%) patients due to adverse events on prior medications. Mean follow-up period was 4 ± 1.67 years. In the last follow-up visits, most of our cohort was relapse free (79.5% vs. 17.8%; p < 0.001) compared to baseline before alemtuzumab treatment while mean EDSS score was reduced (2.21 ± 2.15 vs. 2.41 ± 1.85; p < 0.059). The proportion of PwMS who had MRI activity (new T2/ Gd-enhancing) lesions were significantly reduced compared to baseline (15.1% vs. 82.2%; p < 0.001). NEDA-3 was achieved in 57.5% of (PwMS). NEDA-3 was significantly better in naïve patients (78% versus. 41.5%; p < 0.002) and in patients with disease duration < 5 years, (82.6% v 43.2%; p < 0.002). Several adverse events such as infusion reactions (75.3%), autoimmune thyroiditis (16.4%) and glomerulonephritis (2.7%) were reported.

Conclusion: The effectiveness and safety profile of alemtuzumab in this cohort were consistent with data of clinical trials. Early initiation of Alemtuzumab is associated with favorable outcome.

Keywords: Alemtuzumab; Kuwait; Multiple sclerosis; Real-world evidence; Treatment response.

Conflict of interest statement

Declaration of Competing Interest None.


Similar articles

Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.

López-Real AM, Gonzalez I, Solar DM, Oterino A, Costa E, Pato A, Llaneza MA, García-Estévez DA, Rodriguez-Regal A, Rodriguez M, Peña J.Mult Scler Relat Disord. 2023 Jul;75:104762. doi: 10.1016/j.msard.2023.104762. Epub 2023 May 13.PMID: 37229800

A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.

Bose G, Rush C, Atkins HL, Freedman MS.Mult Scler Relat Disord. 2021 Jul;52:102945. doi: 10.1016/j.msard.2021.102945. Epub 2021 Apr 11.PMID: 33901969

Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.

Zmira O, Halpern AI, Abraham L, Achiron A.Acta Neurol Belg. 2021 Dec;121(6):1513-1518. doi: 10.1007/s13760-020-01375-6. Epub 2020 May 23.PMID: 32447722 Clinical Trial.

Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.

Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, Yang X.Cochrane Database Syst Rev. 2017 Nov 27;11(11):CD010968. doi: 10.1002/14651858.CD010968.pub2.PMID: 29178444 Free PMC article. Review.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.PMID: 24310855 Review.


KMEL References